Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
33,945,050
-
Total 13F shares
-
16,131,666
-
Share change
-
-3,751,499
-
Total reported value
-
$12,093,567
-
Put/Call ratio
-
28%
-
Price per share
-
$0.75
-
Number of holders
-
49
-
Value change
-
-$11,627,173
-
Number of buys
-
20
-
Number of sells
-
31
Institutional Holders of Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) as of Q4 2025
As of 31 Dec 2025,
Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,131,666 shares.
The largest 10 holders included
5AM Venture Management, LLC, Versant Venture Management, LLC, BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, SPHERA FUNDS MANAGEMENT LTD., MILLENNIUM MANAGEMENT LLC, BlackRock, Inc., PLATINUM INVESTMENT MANAGEMENT LTD, GEODE CAPITAL MANAGEMENT, LLC, and Schonfeld Strategic Advisors LLC.
This page lists
49
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.